Zytiga
What Zytiga is used for
Zytiga is indicated with prednisone or prednisolone for: the treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated the treatment of metastatic castration resistant prostate cancer in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Zytiga
- Active substance
- abiraterone
- Disease area
- Prostatic Neoplasms
- Medicine group
- Endocrine therapy
- ATC code
- L02BX03
- Marketing authorisation holder
- Janssen-Cilag International
- Authorised in the EU since
- 2011
Official information
In the USA
Same active substance: Akeega
In India
- Abiraterone acetate: 45 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Zytiga used for?
Zytiga is indicated with prednisone or prednisolone for: the treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated the treatment of metastatic castration resistant prostate cancer in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.
What is the active substance in Zytiga?
Zytiga contains abiraterone.
Who makes Zytiga?
The EU marketing authorisation holder is Janssen-Cilag International.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU